|
1
|
Altay H, Çavuşoğlu Y, Çelik A, Demir Ş,
Kılıçarslan B, Nalbantgil S, Temizhan A, Tokgöz B, Ural D,
Yeşilbursa D, et al: Management of hyperkalemia in heart failure.
Turk Kardiyol Dern Ars. 49 (Suppl 1):S1–S32. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kidney Disease: Improving Global Outcomes
(KDIGO) Diabetes Work Group: KDIGO 2022 clinical practice guideline
for diabetes management in chronic kidney disease. Kidney Int. 102
(Suppl 5):S1–S127. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Collins AJ, Pitt B, Reaven N, Funk S,
McGaughey K, Wilson D and Bushinsky DA: Association of serum
potassium with all-cause mortality in patients with and without
heart failure, chronic kidney disease, and/or diabetes. Am J
Nephrol. 46:213–221. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Al-Omairi A, Abdulnasser Obaid M, Agrawal
I, Abdalla A and Al Rawas AH: Calcineurin inhibitor-induced type IV
renal tubular acidosis in post-bone marrow transplant: Review of
pathophysiology and principles of management. Cureus.
15(e40215)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Nakayama T, Mitsuno R, Azegami T, Sato Y,
Hayashi K and Itoh H: A: Systematic review and meta-analysis of the
clinical impact of stopping renin-angiotensin system inhibitor in
patients with chronic kidney disease. Hypertens Res. 46:1525–1535.
2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bánfi-Bacsárdi F, Muk B, Pilecky D, Duray
GZ, Kiss RG and Nyolczas N: The optimization of guideline-directed
medical therapy during hospitalization among patients with heart
failure with reduced ejection fraction in daily clinical practice.
Cardiology. 148:27–37. 2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hunter RW and Bailey MA: Hyperkalemia:
Pathophysiology, risk factors and consequences. Nephrol Dial
Transplant. 34 (Suppl 3):iii2–iii11. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Heitzmann D and Warth R: Physiology and
pathophysiology of potassium channels in gastrointestinal
epithelia. Physiol Rev. 88:1119–1182. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sousa AG, Cabral JV, El-Feghaly WB, de
Sousa LS and Nunes AB: Hyporeninemic hypoaldosteronism and diabetes
mellitus: Pathophysiology assumptions, clinical aspects and
implications for management. World J Diabetes. 7:101–111.
2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Luo X, Xu J, Zhou S, Xue C, Chen Z and Mao
Z: Influence of SGLT2i and RAASi and their combination on risk of
hyperkalemia in DKD: A network meta-analysis. Clin J Am Soc
Nephrol. 18:1019–1030. 2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ng CT, Lim KX and Loo KN: Bradycardia,
renal failure, atrioventricular nodal blockade, shock, and
hyperkalemia (BRASH) syndrome: A rising entity of severe
bradycardia. Cureus. 15(e35620)2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sevamontree C, Jintajirapan S,
Phakdeekitcharoen P and Phakdeekitcharoen B: The prevalence and
risk factors of hyperkalemia in the outpatient setting. Int J
Nephrol. 2024(5694131)2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chay J, Choo JCJ and Finkelstein EA:
Cost-effectiveness of sodium zirconium cyclosilicate for advanced
chronic kidney patients in Singapore. Nephrology (Carlton).
29:278–287. 2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kosiborod MN, Cherney DZI, Desai AS,
Testani JM, Verma S, Chinnakondepalli K, Dolling D, Patel S, Dahl
M, Eudicone JM, et al: Sodium zirconium cyclosilicate for
management of hyperkalemia during spironolactone optimization in
patients with heart failure. J Am Coll Cardiol. 85:971–984.
2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yoo N, Song YB, Dubinsky I and Altshuler
J: Single dose of sodium zirconium cyclosilicate versus sodium
polystyrene sulfonate in hospitalized patients with hyperkalemia.
Ann Pharmacother. 57:1044–1052. 2023.PubMed/NCBI View Article : Google Scholar
|
